
|Articles|August 1, 2003
Intravitreal triamcinolone shows promise for CRVO
Fort Lauderdale, FL-Intravitreal injection of triamcinolone acetonide (Kenalog, Bristol-Myers Squibb) may be a safe and effective treatment for central retinal vein occlusion (CRVO), said Michael S. Ip, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Rayner announces Sophi Phaco System in the US
2
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
3
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
4
PRIMA retinal implant restores vision in patients with advanced GA
5














































